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ABSTRACT
Young, skeletally mature mice lacking Cx43 in osteocytes exhibit increased osteocyte apoptosis and decreased bone strength,
resembling the phenotype of old mice. Further, the expression of Cx43 in bone decreases with age, suggesting a contribution of
reduced Cx43 levels to the age-related changes in the skeleton.We report herein that Cx43 overexpression in osteocytes achieved by
using the DMP1-8kb promoter (Cx43OT mice) attenuates the skeletal cortical but not trabecular bone phenotype of aged, 14-month-
old mice. The percentage of Cx43-expressing osteocytes was higher in Cx43OT mice, whereas the percentage of Cx43-positive
osteoblasts remained similar to wild-type (WT) littermate control mice. The percentage of apoptotic osteocytes and osteoblasts was
increased in agedWTmice comparedwith skeletally mature, 6-month-oldWTmice, and the percentage of apoptotic osteocytes, but
not osteoblasts, was decreased in age-matched Cx43OT mice. Aged WT mice exhibited decreased bone formation and increased
bone resorption as quantiﬁed by histomorphometric analysis and circulating markers compared with skeletally mature mice.
Further, aged WT mice exhibited the expected decrease in bone biomechanical structural and material properties compared with
youngmice. Cx43 overexpression prevented the increase in osteoclasts and decrease in bone formation on the endocortical surfaces
and the changes in circulating markers in the aged mice. Moreover, the ability of bone to resist damage was preserved in aged
Cx43OT mice both at the structural and material level. All together, these ﬁndings suggest that increased Cx43 expression in
osteocytes ameliorates age-induced cortical bone changes by preserving osteocyte viability and maintaining bone formation,
leading to improved bone strength. © 2018 American Society for Bone and Mineral Research.
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Introduction
Advanced age is associatedwith skeletal fragility as a result ofdecreases in bone quantity and quality due to changes in
the structural and material properties of bone.(1,2) Bone
remodeling, a coordinated process critical for the maintenance
of bone quality, occurs throughout life; however, the rate of
bone turnover signiﬁcantly decreases with advancing skeletal
age.(3,4) Alterations in bone turnover where resorption out-
weighs formation eventually result in bone loss in old age. Initial
age-induced bone loss is observed in trabecular bone due to
decreased osteoblast activity, whereas cortical bone losses occur
later.(5,6) In addition to the alterations in bone structure, bone
material is also affected in aging,(5) as changes in bone mineral
matrix and collagen composition as well as accumulation of
microdamage further contribute to the increased skeletal
fragility with aging.(2)
Numerous studies suggest that the extensive osteocyte
network within the mineralized bone matrix plays an essential
role in orchestrating bone remodeling through cell-cell
communication among neighboring osteocytes and with cells
on the bone surface.(7,8) Consistent with this notion, old age and
conditions of increased skeletal fragility are associated with
reductions in osteocyte viability and increased prevalence of
empty lacunae, and disruptions in the osteocyte network alter
osteocytic regulation of bone remodeling.(9) Osteocytes control
intercellular signaling with distant cells both through the
extracellular release of molecules and cytokines via hemi-
channels formed via connexins (Cx) and directly with adjacent
cells through gap junction channels, formed by connexons
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present on the surface of neighboring cells.(10,11) Cx transmem-
brane proteins are expressed in osteoblasts, osteocytes, and
osteoclasts, with Cx43 being the most highly expressed
connexin in bone.(12)
The critical role of Cx43 in early andmature osteoblasts as well
as in osteocytes has been demonstrated in numerous
studies.(13–15) We previously showed that removal of Cx43
from osteocytes results in a skeletal phenotype that resembles
that of agedmice with increased osteocyte apoptosis, enhanced
osteoclast recruitment to bone surfaces, and defective bone
material properties.(13,16) Further, Cx43 is signiﬁcantly decreased
in old mice and humans.(4,16) Overall, these ﬁndings demon-
strate the essential role that Cx43 plays in maintaining osteocyte
viability and bone homeostasis, thus underscoring the potential
contribution of reduced levels of Cx43 in osteocytes to the bone
weakness in aging. However, the speciﬁc role that osteocytic
Cx43 plays in controlling bone structure and strength in aging
has not been studied.
We investigated here whether expression of an osteocyte-
targeted Cx43 transgene could preserve osteocyte viability and
attenuate the skeletal phenotype in aged mice, using mice in
which the DMP1-8kb promoter targeted Cx43 expression to
osteocytes (Cx43OT mice). Overall, the results of this study
demonstrate that increased osteocytic Cx43 expression partially
preserves osteocyte viability and maintains cortical bone quality
in aged mice. Because overexpression of Cx43 in osteocytes
does not signiﬁcantly affect cancellous bone, these ﬁndings also
point to a site-speciﬁc effect of Cx43 in osteocytes.
Materials and Methods
Mice
DMP1-8kb-Cx43/GFP mice (abbreviated as Cx43OT) were
generated at the Transgenic and KO Mouse Core (IUSM) with
the Cx43 transgene, generated by S and M Harris (UTSHC, San
Antonio, TX, USA), using the DMP1-8kb promoter(17) CMV-Cx43/
GFP(18) constructs (Supplemental Fig. S1A). The presence of the
transgenewas evaluated by PCR in genomic DNA extracted from
ear notch samples using primer sets for Cx43 and GFP. DMP1-
GFP mice were used as positive controls for GFP.(17) GFP
expression in DNA from Cx43OT mice was detected by PCR but
not by ﬂuorescent microscopy, possibly because of low
expression resulting from the transgene construct design in
which GFP was after IRES.
All mice were maintained on a C57BL/6Nhsd background
(Envigo, Indianapolis, IN, USA) and littermates were used as
controls. Mice were fed a regular diet and water ad libitum and
were maintained on a 12-hour light/dark cycle. Mice were born
at the expectedMendelian frequency, were fertile, and exhibited
a similar size and weight to wild-type (WT) littermate mice at
birth. Female skeletally mature 6-month-old and aged 14-
month-old mice were used. Based on published data, our 6-
month-old mice are equivalent to 20-year-old humans, whereas
the 14-month-old mice correspond to middle-aged humans at
the end of their reproductive stage of life (approximately
58 years old).(19) For dynamic histomorphometric studies, mice
received intraperitoneal injections of calcein (30mg/kg) and
alizarin red (50mg/kg) (Sigma Chemical, St. Louis, MO, USA) 7
and 2 days before euthanization, as published.(20) The protocols
involving animal procedures were approved by the Institutional
Animal Care and Use Committee of Indiana University School of
Medicine.
Osteoblast and osteocyte isolation
Calvaria cells were isolated fromCx43OTmice bred to DMP1-8kb-
GFP mice, which have GFP-labeled osteocytes.(16,21) Cells were
isolated by sequential 20-minute digestions using a trypsin/
EDTA/collagenase Pmixture as previously described.(22) The ﬁrst
digestion was discarded, and cells from all other digestions were
pulled. GFP-expressing cells (osteocyte-enriched) were sepa-
rated from GFP-negative cells (osteoblast-enriched) by sorting
the cell suspension using a FACSAria ﬂow cytometer (BD
Biosciences, Sparks, MD, USA) at the Indiana University Flow
Cytometry Core Facility, as published.(23)
RNA extraction and real-time PCR (qPCR)
Total RNA was isolated and puriﬁed using TRIzol (Invitrogen,
Grand Island, NY, USA). Reverse transcription was performed
using a high-capacity cDNA kit (Applied Biosystems, Foster City,
CA, USA). qPCR was performed using the Gene Expression Assay
Mix TaqMan Universal Master Mix containing 80 ng of each
cDNA template using an ABI 7900HT real-time PCR system. The
housekeeping gene glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used. Primers and probes were commercially
available (Applied Biosystems) or were designed using the Assay
Design Center (Roche Applied Science, Indianapolis, IN, USA).
Relative expression was calculated using the DCt method.(23)
Immunohistochemistry
Cx43 expression in osteocytes and osteoblasts was visualized in
parafﬁn-embedded femora from 2-month-old mice, as de-
scribed.(23,24) Brieﬂy, sections were deparafﬁnized, treated with
3% H2O2, blocked with rabbit serum, and incubated with 1:1000
anti-Cx43 (C6219) (Sigma-Aldrich, St. Louis, MO, USA). Sections
were incubated with the corresponding biotinylated secondary
antibody followed by avidin conjugated peroxidase (Vectastain
Elite ABC Kit; Vectora Laboratories, Burlingame, CA, USA). Color
was developed with a diaminobenzidine substrate chromogen
system (Dako, Glostrup, Denmark). Sections were counter-
stained with 2% methyl green.(16) Cells expressing the protein
are brown, whereas negative cells are green-blue. Non-immune
IgGs were used as negative controls.
Western blotting analysis
Whole protein extracts from osteocyte-enriched long bones
(cortical bone preparations), calvaria bones, and soft tissue
samples were prepared as published.(16,25) Protein levels were
measured by Western blot analysis. Membranes were probed
with primary antibodies, rabbit anti-connexin43 (C6219), and
mouse anti-b-actin (A5316) (Sigma-Aldrich) diluted 1:1000,
overnight at 4°C, followed by incubation with corresponding
secondary antibodies conjugated with horseradish peroxidase
(Santa Cruz Biotechnology, Dallas, TX, USA) for 4 hours at room
temperature. Membranes were developed with an enhanced
chemiluminescence Western blotting substrate kit (Pierce
Biotechnology Inc., Rockford, IL, USA). Bands were quantiﬁed
using ImageJ.
Bone mineral density (BMD) by dual-energy X-ray
absorptiometry (DXA)
BMD was measured monthly by DXA using a PIXImus
densitometer (GE Medical Systems, Lunar Division, Madison,
WI, USA).(20) BMD measurements included total BMD (excluding
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the head and tail), entire femur (femoral BMD), and L1 to L6
vertebra (spinal BMD).(23) Calibration was performed before
scanning with a standard phantom, as recommended by the
manufacturer.
Apoptosis
Osteocyte and osteoblast apoptosis was detected in undecalci-
ﬁed vertebral bone sections and parafﬁn-embedded femur
sections by TdT-mediated dUTP nick-end labeling (TUNEL) using
a modiﬁed version of a commercial kit (EMD Millipore, Billerica,
MA, USA) in sections counterstained with 2% methyl green, as
published.(16)
Serum biochemistry
Plasma collected 3 hours after fasting by cheek bleeding was
aliquoted and stored at80°C.(20) N-terminal propeptide of type
I procollagen (P1NP) (Immunodiagnostic Systems Inc., Fountain
Hill, AZ, USA, cat. #AC-33F1) and C-telopeptide fragments (CTX)
(RatLaps, Immunodiagnostic Systems Inc., cat. #AC-06F1) were
measured as published.(16,26)
Micro-computed tomography (mCT) analysis
Femora and L4 vertebrae were dissected, wrapped in saline-
containing gauze, and frozen at 20°C.(26) Trabecular morphol-
ogy of the L4 vertebral body was obtained using the Skyscan
1172 system with a 60 kV source, 0.5mm Al ﬁlter, 0.7 degree
rotation, and two-image averaging with an isotropic voxel size
of 6mm.(27) Femora were scanned using a 55 kV source, 0.5mm
Al ﬁlter, 0.7 degree rotation, and two-image averaging with an
isotropic voxel size of 9mm using a SkyScan 1176 system
(SkyScan, Kontich, Belgium). Scans were reconstructed and
analyzed using manufacturer software. Two different systems
were used because of constrained availability. Nomenclature is
reported in accordance with suggested guidelines for mCT.(28)
Bone histomorphometry
Femora and vertebrae were dissected, ﬁxed in 10% neutral-
buffered formalin, and embedded in methyl methacrylate, as
published.(26) Dynamic histomorphometric measurements were
performed in unstained femoral mid-diaphysis and vertebrae
sections.(26) Static histomorphometric analysis was performed
on sequential plastic-embedded vertebra sections stained with
von Kossa/McNeal for osteoblasts and TRAP/Toluidine blue for
osteoclasts. Osteoclasts were also quantiﬁed on parafﬁn-
embedded femur sections. Analysis was performed by blinded
investigators using the OsteoMeasure high-resolution digital
video system (OsteoMetrics Inc., Decatur, GA, USA).(25,29) The
terminology and units used are those recommended by the
Histomorphometry Nomenclature Committee of the ASBMR.(28)
Biomechanical testing
Three-point bending testing of the femoral mid-diaphysis was
performed following previously published protocols.(26) Axial
compression of the L4 vertebrae was performed after removing
the vertebral processes and endplates. A rate of 0.5mm/minwas
used to load the vertebral bodies until failure, as previously
described.(30) Structural mechanical properties were determined
from the load-displacement curves using standard deﬁnitions,
whereas material-level properties were derived from the load-
displacement curves, cross-sectional moments of inertia, and
the distances from the centroid to the tensile surface using
geometrical data determined by mCT and standard beam-
bending equations.(20)
Statistical analysis
Datawere analyzed by using SigmaPlot (Systat Software Inc., San
Jose, CA, USA). Differences were evaluated either by two-way
ANOVA, with post hoc analysis using Tukeymethod or Student’s
t test, as appropriate. Differences were considered signiﬁcant
when p< 0.05.
Results
Effective expression of an osteocyte targeted Cx43
transgene in Cx43OTmice
To test the effect of Cx43 levels on osteocyte viability and bone
homeostasis in aged mice, we generated a transgenic mouse
model that expresses a DMP1-8kb-Cx43/GFP transgene primar-
ily in osteocytes (Cx43OT mice) (Supplemental Fig. S1A). An
ampliﬁed fragment of 297 bp corresponding to the Cx43 allele
and of 525 bp to the GFP allele was used to generate transgenic
Cx43OTmice. Of the 11 potential transgenic founders generated,
two mice were found to express the exogenous Cx43 and GFP
genes. Because of higher Cx43 protein levels in the founder
mouse #82 (data not shown), offspring generated from this
mouse were used for the outlined studies. Expression of both
exogenous Cx43 and GFP were transmitted to half of the
offspring when crossed with a WT mouse, as expected
(Supplemental Fig. S1B). To conﬁrm that our DMP1-8kb-Cx43/
GFP transgene is primarily expressed in osteocytes and not in
osteoblasts, Cx43OT mice were crossed with DMP1-8kb-GFP
mice.(16,21) GFP-positive osteocytes (Ot) isolated by FACS
expressed high levels of the osteocyte markers SOST, DMP1,
and FGF23, whereas the osteoblast marker keratocan was low
(Fig. 1A). GFP-negative osteoblasts (Ob) had undetectable levels
of SOST and DMP1, whereas keratocan expression was higher,
validating the identity of the cell populations. Cx43 expression
was increased in the GFP-positive osteocytes and decreased in
the GFP-negative osteoblasts isolated from Cx43OT compared
with WT littermate mice, demonstrating osteocyte-speciﬁc
expression of the transgene. Moreover, the percentage of
Cx43-positive osteocytes, detected by Cx43 immunostaining,
was increased twofold in Cx43OT mice compared with WT mice,
whereas the percentage of Cx43-positive osteoblasts on the
bone surface was similar, although it showed a tendency toward
decrease (Fig. 1B), similar to the Cx43 mRNA levels in
osteoblastic cells (Fig. 1A). Cx43 expression at the protein level,
measured by Western blotting analysis, was not increased in
marrow-ﬂushed cortical bone preparations or in calvaria lysates
(Fig. 1C), possibly because of the presence of other Cx43-
expressing cells, such as osteoblasts.(16) Further, no changes in
Cx43 protein were detected in the heart, kidney, brain, or
skeletal muscle of Cx43OT mice compared with WT mice.
Similar to mice lacking osteocytic Cx43,(16) overexpression of
osteocytic Cx43 in Cx43OT mice did not exhibit changes in BMD
during growth in female (Fig. 1D) or malemice (data not shown),
demonstrating that Cx43 in osteocytes is not involved in bone
mass accrual. Total, femoral, and spinal BMD of the Cx43OT and
WT mice by DXA were similar up to 5.5 months, except for a
slight increase in total and femoral BMD in the female Cx43OT
mice at age 2 months, which was consistent with reduced BMD
at this age in mice lacking osteocytic Cx43.(16) No decreases in
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Fig. 1. Effective osteocyte targeted Cx43 transgene expression in DMP1-8kb-Cx43/GFP (Cx43OT) mice. (A) mRNA expression in primary osteoblasts and
osteocytes isolated from DMP1-8kb-GFP mice expressing GFP under the control of the 8-kb fragment of the DMP1 promoter. Ob¼ osteoblastic cells;
Ot¼ osteocytic cells; n.d.¼non-detectable. Bars representmean SD of triplicatemeasurements, p< 0.05, t test versusWT cells. (B) Cx43 expression in
osteocytes and osteoblasts was evaluated in the femoral mid-diaphysis of Cx43OT and WT littermate mice stained with a non-immune IgG or anti-Cx43
polyclonal antibody, counterstained with 0.2% methyl green. Bars represent mean SD, p< 0.05, t test versus WT mice, n¼ 6 WT and n¼ 4 Cx43OT.
Representative images of Cx43-negative (arrow, white) and Cx43-positive (arrow, red) osteocytes are shown. Scale bar¼ 25mm. (C) Cx43 protein levels
measured inmarrow-ﬂushed cortical bone preparations, calvarial bones, and in the soft tissues of Cx43OT andWTmice byWestern blot correct byb-actin
levels, n¼ 3. (D) Total body, spinal, and femoral BMD were measured from 1 to 14 months of age by DXA in females, n¼ 13 WT and n¼ 11 Cx43OT.
Symbols represent SD, p< 0.05 versus WT littermates by t test.
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total or femoral BMD were observed in either genotype up to
14 months compared with 5.5-month-old mice. On the other
hand, spinal BMDbegan to decline at 9.5months in theWTmice,
and by 12 months decreases in spinal BMD were detected in
both genotypes.
Increased Cx43 expression reduces osteocyte apoptosis
in aged mice
To investigate the effects of aging on osteocyte viability,
apoptosis was quantiﬁed in the different bone compartments
of the lumbar vertebra and femur. No changes in the
percentage of apoptotic osteocytes or osteoblasts were
detected between the two genotypes at 6 months of age
(young mice) (Fig. 2A). Aged WT mice exhibited a 6- and 5.5-
fold increase in osteocyte apoptosis in the cortical and
cancellous vertebral bone, respectively, and a 22-fold increase
in cancellous osteoblast apoptosis compared with young WT
mice.(3,31) Cortical and cancellous osteocyte apoptosis was
higher in aged compared with young animals even in Cx43OT
mice; however, osteocyte apoptosis was 40% lower in the
cortical bone and 24% lower in the cancellous bone of the
vertebra in the aged transgenic mice compared with WT mice.
Similar decreases were detected in the femoral cortical bone of
aged transgenic mice compared with WT mice (Fig. 2B). In
contrast, the prevalence of apoptotic cancellous osteoblasts
was increased approximately 40% with aging in both
genotypes and no differences in osteoblast viability were
detected between the two genotypes at 14 months of age
(Fig. 2A). Thus, increased expression of Cx43 in osteocytes
partially prevents the increase in osteocyte apoptosis induced
by aging.
Endocortical bone formation is maintained in aged
Cx43OT mice
Aging led to alterations in the bone turnover markers in the WT
mice, with a 42% decrease in the formation marker P1NP and a
34% increase in the resorption marker CTX in aged compared
with young WT mice (Fig. 3A). On the other hand, P1NP levels
were increased 66% and CTX levels were decreased 24% in aged
compared with young Cx43OT mice. Moreover, although no
changes in P1NP were detected between the two genotypes in
young mice, aged Cx43OT mice exhibited 135% higher P1NP
levels compared with WT mice of the same age. Further, at
6months of age, CTX levels were slightly increased in the Cx43OT
Fig. 2. Expression of Cx43 in osteocytes reduces osteocyte apoptosis induced with aging. (A) Percentage of apoptotic (TUNEL-positive) cortical and
cancellous osteocytes, as well as cancellous osteoblasts were scored in vertebral bone sections. Bars representmean SD, p< 0.05, versus 6-month-old
genotype-matchedmice by two-wayANOVA, Tukey, black line: p< 0.05, versus old controlmice by t test. Six-month-oldmice: n¼ 9WT and n¼ 8 Cx43OT,
14-month-old mice: n¼ 8WT and n¼ 7 Cx43OT. Representative images of TUNEL-negative (arrow, white) and positive (arrow, red) osteocytes are shown.
Scale bar¼ 2.5mm. (B) Percentage of apoptotic cortical osteocytes were scored in longitudinal distal femur sections from 14-month old mice. Bars
represent mean SD, p< 0.05 versus WT littermates by t test, n¼ 7WT and n¼ 9 Cx43OT. Representative images of TUNEL-negative (arrow, white) and
positive (arrow, red) osteocytes are shown. Scale bar¼ 6.25mm.
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Fig. 3. Fourteen-month-old Cx43OT mice exhibit enhanced endocortical bone formation and decreased resorption. (A) Circulating levels for P1NP and
CTX were measured by ELISA in serum collected from 6- and 14-month-old mice. Six-month-old mice: n¼ 10 WT and n¼ 9 Cx43OT, 14-month-old mice:
n¼ 11WT and n¼ 9 Cx43OT. (B) Periosteal and endosteal MS/BS, MAR, and BFR/BS weremeasured in unstained sections from the femoral mid-diaphysis.
Six-month-old mice: n¼ 9WT and n¼ 9 Cx43OT, 14-month-oldmice: n¼ 8WT and n¼ 7 Cx43OT. Representative images are shown. Scale bars¼ 100mm.
(C) N.Oc/BS, Oc.S/BS, ES/BS were scored in femoral cortical mid-diaphysis after staining for TRAP/Toluidine blue in Cx43OT and WT mice. Six-month-old
mice: n¼ 9 WT and n¼ 9 Cx43OT, 14-month-old mice: n¼ 5 WT and n¼ 7 Cx43OT. Osteoclasts on the bone surface (arrow, red) are shown. (D) Cortical
bone geometry was evaluated by mCT in the femoral mid-diaphysis. Six-month-old mice: n¼ 8 WT and n¼ 9 Cx43OT, 14-month-old mice: n¼ 8 WT and
n¼ 6 Cx43OT. Representative reconstructed images of the femoral mid-diaphysis are shown. Bars represent mean SD, p< 0.05, versus 6-month-old
genotype-matched mice by two-way ANOVA, Tukey, black line: p< 0.05, versus old control mice by t test.
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mice, whereas at 14 months CTX levels were 28% lower
compared with aged WT mice.
No changes in periosteal bone formation parameters,
mineralizing surface per bone surface (MS/BS), mineral appo-
sition rate (MAR), or bone formation rate per bone surface (BFR/
BS), were detected between the two genotypes at either age in
the femoral mid-diaphysis (Fig. 3B). On the other hand, dynamic
histomorphometric analysis revealed that all bone formation
indexes were increased on the endocortical surface in the
Cx43OT versus WT mice at 14 months but not at 6 months
(Fig. 3B), consistent with the increased P1NP levels observed in
the 14-month-old Cx43OT mice. As for MS/BS, the surfaces
occupied by single and double labels on the periosteum were
similarly increased by aging independently of the genotype of
the mice, whereas Cx43 overexpression did not alter these
parameters (Supplemental Fig. S2A). On the other hand, the
percent single-labeled surface on the endocortex was increased
by aging and decreased by the transgene, whereas double-
labeled-covered surface was decreased in 14-month-old wild-
type mice but increased in Cx43OT mice compared with the
corresponding 6-month-old mice (Supplemental Fig. S2B).
Further, similar to the decreases in CTX observed in the
Cx43OT mice at 14 months of age, static histomorphometric
analysis of the endocortical surface of the femoral mid-diaphysis
revealed a 2.5-fold reduction in the number of osteoclasts per
bone surface (N.Oc/BS), a 1.9-fold decrease in bone surface
occupied by osteoclasts (Oc.S/BS), and a 1.9-fold reduction in the
eroded bone surface (ES/BS) in the 14-month-old Cx43OT
compared with WT mice (Fig. 3C).
Cortical bone mechanical properties are preserved in
aged Cx43OT mice
mCT analysis revealed that both WT and Cx43OT mice exhibited
the expected age-related skeletal alterations in cortical bone
geometry of the femoral mid-diaphysis, with increased marrow
cavity area, as well as decreased cortical thickness (Ct.Th) and
bone area/tissue area (BA/TA) in aged mice (Fig. 3D). Further, we
did not detect changes in the cortical bone geometry of the
femur between the genotypes at either age, aside from a slight
increase in marrow cavity area of the aged Cx43OT mice.
In contrast, biomechanical studies of the femur by 3-point
bending revealed that increased osteocytic Cx43 expression
enhanced the structural and material bone properties in
skeletally mature mice and prevented the loss of these
properties in aged mice (Fig. 4). At 6 months of age, Cx43OT
mice exhibited enhanced femoral structural properties with
increased yield force, ultimate force, stiffness, and work to yield
(Fig. 4A), as well as increases in the material properties yield
stress, modulus, and resilience (Fig. 4B). Moreover, aging in the
WTmice resulted in decreases in both the structural andmaterial
properties of the femoral bone, with decreases in ultimate force/
stress, stiffness/modulus, postyield/total work, and toughness.
Further, decreases were detected in the pre-yield properties
with lower yield force/stress of WT bones from aged compared
with youngmice. In contrast, although decreases were detected
in ultimate force/stress and stiffness/modulus of the femur from
14-month-old Cx43OT mice, displacement/strain to yield were
signiﬁcantly increased compared with 6-month-old transgenic
mice. Aged Cx43OT mice also exhibited increases in the pre-yield
properties, yield force/stress, displacement/strain to yield, and
work to yield/resilience compared with WT mice at the same
age. In contrast to the effects of osteocytic Cx43 overexpression
on pre-yield properties, osteocytic Cx43 deletion results in
reductions in the pre-yield properties of the cortical bone at
both the structural and material level (Supplemental Table S1).
Taken together, our data suggest that overexpression of
osteocytic Cx43 in aging preserves certain cortical bone
mechanical properties, maintaining the ability of the bone to
absorb energy without damaging.
Increased osteocytic Cx43 does not prevent age-induced
cancellous bone loss
Analysis of cancellous bone microarchitecture by mCT revealed
that 6-month-old Cx43OT mice exhibited increased trabecular
thickness (Tb.Th) in the lumbar vertebra, without changes in the
other trabecular bone parameters (Fig. 5A). Consistent with the
increases in vertebral cancellous bone detected by mCT,
vertebral compression testing detected increases in ultimate
load/stress in the Cx43OT comparedwithWTmice at 6months of
age (Fig. 5B). However, by 14 months of age, differences in
cancellous bone between the two genotypes were no longer
detected. Moreover, although aging led to a loss of vertebral
cancellous bone BV/TV and Tb.N in both genotypes, decreases in
vertebral Tb.Th were only detected in the 14-month-old Cx43OT
mice (Fig. 5A). Further, stiffness/modulus of the vertebra were
decreased in aged mice from both genotypes, whereas
decreases in ultimate load/stress were only detected in the
14-month-old Cx43OT mice (Fig. 5B).
Consistent with the decreases in vertebral cancellous bone
observed with aging in both WT and trangenic mice,
histomorphometric analysis revealed decreases in MS/BS and
BFR/BS (Fig. 6A) along with reductions in osteoblast number (N.
Ob/BS) and surface (Ob.S/BS) (Fig. 6B) in the aged compared
with young mice of both genotypes. Further, osteoclast
parameters, N.Oc/BS, Oc.S/BS, and ES/BS, were higher in both
genotypes at 14-month-old compared with 6-month-old mice.
At 6 months of age, cancellous MAR and BFR/BS were reduced
(Fig. 6A) and Ob.S/BS was decreased along with a tendency
toward decrease in N.Ob/BS (Fig. 6B) in Cx43OT mice compared
with WT mice. At 14 months of age, MAR was still decreased in
Cx43OT compared with WT mice, whereas no differences in N.
Ob/BS or Ob.S/BS were detected. On the other hand, no changes
in osteoclasts were detected between the genotypes at either
age (Fig. 6C). Taken together, these pieces of evidence suggest
that increased osteocytic Cx43 does not prevent and may
actually enhance cancellous bone loss induced with aging.
Discussion
Previous work from our laboratory demonstrated that Cx43 is
critical for osteocyte survival and removal of osteocytic Cx43
leads a skeletal phenotype similar to that observed in aging with
increases in osteocyte apoptosis and enhanced osteoclast
recruitment, as well as deﬁcits in the material properties of the
cortical bone.(13,16) In this study,we examined the contributionof
osteocytic Cx43 to the skeletal phenotype of aged mice, using
Cx43OTmice expressing aCx43 transgene targeted toDMP1-8kb-
expressing cells. We show that the prevalence of apoptotic
osteocyteswas signiﬁcantly reduced in the cortical and to a lesser
extent in the cancellous boneof 14-month-old Cx43OT compared
with WT mice, further demonstrating the critical role of Cx43 in
maintaining osteocyte viability. In addition, we found that in
aged Cx43OT mice, reductions in osteocyte apoptosis were
accompanied by changes in bone remodeling with increased
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formation anddecreased resorption along the endocortical bone
surface. Although this did not alter long bone geometrical
changes induced with aging, improvements in the cortical
mechanical properties were observed at the material level. It is
possible that the aging process has just started in our 14-month-
old animals, and although changes were detected at the cellular
levels, we did not allow enough time for these alterations to
translate into structural changes. Consistent with this possibility,
we did not detect increases in bone mass in the aged compared
with the young Cx43OT mice by BMD or mCT analyses, even
though the circulating markers suggest higher bone mass in the
older animals. The reason for this discrepancy is not clear.
However, it is possible that because the aging process may have
just started in our animals and although changes were detected
at the cellular levels, we did not allow enough time for these
alterations to translate into structural changes. Furthermore, we
cannot rule out the possibility that the moderate expression of
the transgene in osteocytes and a potential uneven expression in
femoral versus vertebral bonemay provide some explanation for
the weak bone mass phenotype of Cx43OT mice.
In contrast, despite the increases in cancellous bone at
6 months of age in the Cx43OT compared with WT mice and
maintenance of spinal BMD at 9.5 months, age-induced
cancellous bone losses were not prevented in the Cx43OT
mice by 14 months of age. These ﬁndings are consistent with
previous reports demonstrating that removal of osteocytic Cx43
does not alter cancellous bone.(16) All together, our data
demonstrate that Cx43 maintains osteocyte viability in both
cortical and cancellous bone and that preservation of osteocyte
viability appears to be critical for the maintenance of cortical
bone quality in aging, although cancellous bone is still lost.
Furthermore, increased Cx43 expression in osteocytes partially
ameliorates the age-induced skeletal changes by preserving
bone turnover, which likely improves cortical bone mechanical
properties but does not prevent against cancellous bone loss in
old age.
Bone fragility in aging individuals results not only from the
loss of bone mass but also from deﬁcits in bone quality.(5) The
ﬁndings of the present study highlight the essential role of Cx43
in preserving osteocyte viability and maintaining the bone
Fig. 4. Cx43OT mice exhibit increased cortical bone resilience to fracture that is maintained with advanced age. Cortical bone biomechanical properties
structural (A) and material (B) were evaluated by femoral 3-point bending testing. Six-month-old mice: n¼ 7 WT and n¼ 5 Cx43OT, 14-month-old mice:
n¼ 11 WT and n¼ 8 Cx43OT. Bars represent mean SD, p< 0.05, versus 6-month-old genotype-matched mice by two-way ANOVA, Tukey, black line:
p< 0.05, versus old control mice by t test.
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mechanical properties in aging. Age-related declines in bone
material properties are accompanied by changes in the
distribution and architecture of the cortical and trabecular
bone.(6) We found that both agedWT and Cx43OTmice exhibited
the expected age-related increases in long bone diameter
accompanied by decreases in BA/TA and cortical thickness.
These changes in microarchitecture led to a decrease in the
biomechanical properties of the bone at both the structural and
material level. On the other hand, although decreases in the
material properties were detected in the aged compared with
skeletally mature WT mice, aged Cx43OT mice partially
maintained these biomechanical properties at both the
structural and material level, when compared with the 6-
month-old mice. Further, pre-yield mechanical measurements
were all increased in aged Cx43OT comparedwith agedWTmice.
Interestingly, the pre-yield properties of the cortical bone in
mice lacking osteocytic Cx43 were also reduced at both the
structural and material level, whereas deﬁcits in bone post-yield
properties were only detected at the material level.(13) Based on
the fact that we did not detect differences in cortical bone mass
or geometry between the two genotypes at 14 months of age, it
is reasonable to speculate that the increases in the structural and
material properties in the 14-month-old Cx43OT mice are not
due to changes in bone architecture but are likely due to other
factors at the level of the collagen/mineral. Thus, it is possible
that the enhanced capability of the cortical bone of aged Cx43OT
mice to resist damage is due to changes in bone material as a
result of increased osteocyte viability.
Bone quality depends not only on the geometry and
microarchitecture of the bone but also on its material
composition.(1,2) Bone material properties include mineral
content, collagen composition, and microdamage accumula-
tion.(1) Numerous studies have demonstrated the critical role
that osteocytes play in sensing mechanical stimuli and
coordinating targeted bone remodeling to repair damaged
areas.(7,32) Decreases in osteocyte viability have been observed
in many conditions underlying bone loss.(9) However, the
speciﬁc mechanisms by which viable osteocytes prevent bone
fragility in aging are not known. In the current study, we found
that maintenance of osteocyte viability in the 14-month-old
Cx43OT mice is associated with preserved cortical bone elastic
material properties and an improved resilience.
Preliminary gene expression measurements showed that
increased expression of Cx43 in osteocytes results in higher
levels of keratocan (a proteoglycan) in osteocytic cells
(Fig. 1A) and, not shown, Chsy1 (a glucosaminoglycan) and
Lox (lysil oxidase, an enzyme involved in collagen matura-
tion) in bone preparations. Interestingly, deletion of Cx43
from osteocytic cells results in decreased levels of Lox,(13)
suggesting that, as with the biomechanical properties, Cx43
deletion and overexpression leads to opposite effects on
collagen-related genes. Further studies are needed to
understand the mechanism for the changes in the material
properties of the bone of mice expressing DMP1-Cx43. In
addition, whether the improved ability of the bone to resist
damage is due to prevention of microdamage accumulation
Fig. 5. Cx43OTmice are not protected against age-induced loss of cancellous bonemass. (A) Cancellous bonemicroarchitecturewas evaluated bymCT in
the distal femur L4 vertebra. Six-month-old mice: n¼ 7 WT and n¼ 5 Cx43OT, 14-month-old mice: n¼ 14 WT and n¼ 11 Cx43OT. Representative
reconstructed 3D mCT images are shown. (B) Mechanical testing of the structural and material properties was evaluated by axial compression on the L4
vertebra. Six-month-old mice: n¼ 7WT and n¼ 7 Cx43OT, 14-month-old mice: n¼ 13WT and n¼ 10 Cx43OT. Bars represent mean SD, p< 0.05, versus
6-month-old genotype-matched mice by two-way ANOVA, Tukey, black line: p< 0.05, versus old control mice by t test.
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or direct preservation of the bone material by living
osteocytes or a combination of both remains to be
determined.
Findings from numerous studies have consistently shown the
differential role of osteocytic Cx43 in the cortical and cancellous
bone compartments.(12) Removal of Cx43 from mature osteo-
blasts and osteocytes or exclusively from osteocytes results in
cortical bone changes but does not alter cancellous bone.(13,16)
Further, other studies have shown that expression of a truncated
Cx43 lacking the c-terminus domain can negatively affect
cancellous bone, whereas heterozygous deletion of Cx43
improves cancellous bone.(20,33) Our ﬁndings that osteocyte-
targeted Cx43 transgene expression was sufﬁcient to reduce
osteocyte apoptosis in the cortical and to a lesser extent in the
cancellous bone compartments, whereas changes in bone
turnover and improvements in the mechanical properties of the
bone were only observed in cortical bone, further demonstrate
the differential actions of Cx43 in the two bone compartments.
In summary, the ﬁndings from the current study further
highlight the critical role osteocytes play in the maintenance of
cortical bone structure and mechanical properties in aging and
demonstrate the requirement of Cx43-mediated actions in
osteocytes for the preservation of osteocyte viability and cortical
bone quality in aging. On the other hand, osteocytic Cx43 does
not appear to play a critical role in maintaining cancellous bone
in aged mice.
Fig. 6. Expression of osteocytic Cx43 does not alter changes in cancellous osteoblast or osteoclast activity induced with aging. (A) Vertebral cancellous
bone MS/BS, MAR, and BFR/BS were measured in unstained longitudinal vertebral sections. Six-month-old mice: n¼ 9 WT and n¼ 7 Cx43OT, 14-month-
old mice: n¼ 8 WT and n¼ 8 Cx43OT. Representative images show green and red ﬂuorochrome levels. (B) N.Ob/BS, Ob.S/BS, and O.Th were scored in
lumbar vertebra sections stained with von Kossa/McNeal. Six-month-old mice: n¼ 9 WT and n¼ 8 Cx43OT, 14-month-old mice: n¼ 7 WT and n¼ 7
Cx43OT. Representative osteoblast images are shown (arrow, red). (C) Cancellous osteoclasts were scored in TRAP/Toluidine blue-stained vertebral bone
sections. N.Oc/BS, Oc.S/BS, and ES/BS are reported. Six-month-old mice: n¼ 10 WT and n¼ 8 Cx43OT, 14-month-old mice: n¼ 7 WT and n¼ 8 Cx43OT.
Representative osteoclast images are shown (arrow, black). Bars represent mean SD, p< 0.05, versus 6-month-old genotype-matched mice by two-
way ANOVA, Tukey, black line: p< 0.05, versus old control mice by t test. Scale bars¼ 100mm.
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